BioSpace News Archive

Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit.

Pardes Biosciences, Inc. announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT / 12:00 a.m. PT.

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the “Company” or “Odyssey”), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”).

Albireo Pharma, Inc. (Nasdaq: ALBO) today announced the acceptance of two late breakers, including one late breaker with new data from the Phase 3 ASSERT study, to be presented as an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2022, November 4 – 8, 2022.

Quoin Pharmaceuticals Ltd. announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, announces positive results from its ongoing Next Generation Capecitabine (NGC) Phase 1B trial.

Galen Robotics, the Digital-Surgery-as-a-Service ™ pioneer, today announced it has completed the 1st close for an oversubscribed Series A round with $15 million in funding, including investment from Ambix Healthcare Partners, from Menlo Park, CA.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September 30, 2022, after the market closes on November 8, 2022.

LuminUltra, the global leader in applied molecular diagnostics, announced today the launch of the LuminUltra GeneCount® qPCR Corrosion Collection — a complete suite of DNA-based monitoring tools to address microbiologically influenced corrosion (MIC).

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the quarter ended September 30, 2022.